降纤酶双盲对照治疗急性脑梗死109例

Defibrase Therapeutical Effects in 109 Cases of Acute Cerebral Infarction Patients with Double Blind Control Method

目的 评价降纤酶治疗急性脑梗死的临床疗效及与中药川芎嗪的比较。 方法 采用前瞻性、随机、双盲对照的方法。选择 2 4 h内的患者。降纤酶第 1天 1 0 u,第 3、 5天各 5 u静滴。 结果 降纤酶组急性期治愈率高于对照组 ,有显著差异 ;1 2周治愈率接近。神经功能缺损评分及 Barthel指数略好于对照组 ,但无显著差异。降纤酶组治疗后纤维蛋白原明显降低 ,与治疗前及对照组比较 ,有非常显著差异。结论 降纤酶有显著降低血纤维蛋白原作用 ,对 2 4 h内急性脑梗死疗效较川芎嗪略好。无明显毒副作用。

Objective Tis study is to evaluate the defibrase therapeutical effects in the patients of acute cerebral infarction and compare the effects with Chinese herb ligustrazini treatment Method The study is a prospective,random allocation,and double blind control test The acute cerebral infarction patients in 24h were selected clinically to observe the defibrase therapeutic effects in the first day/10u,3 and 5 days/5u intravenous drip respectively Results The curative ratio of defibrase group was significantly higher than control group in acute phase but there was almost no difference in 12 weeks Neurologic deficit marks and Barther index were slightly better than control group but no significance observed After treatment,fibrinogen was decreased obviously i defibrase group Compared with pretreatment and control group the differences were statistics distinct Conclusion Defibrase can obviously decrease blood fibrinogen It's better than ligustrazini in the 24h acute cerebral infarction patients and there was no side effects observed